Clinical Trial
doi: 10.3109/02841868709113713.
Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer
Affiliations
- PMID: 3128309
- DOI: 10.3109/02841868709113713
Item in Clipboard
Clinical Trial
Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer
Acta Oncol.
1987.
Abstract
The toxicities of oral Ftorafur (1 g/m2/day 1-21) and intravenous 5-fluorouracil (5-FU) (500 mg/m2/day 1-5) were compared in a prospective randomized study in patients with colorectal cancer. The treatment courses were repeated every 6th week. Leucopenia was more common after 5-FU. Leucocyte nadir in connection with first treatment cycle was on average seen on day 15 in patients receiving 5-FU and on day 28 in patients receiving Ftorafur. Significantly more patients on 5-FU developed stomatitis. There was no difference in the number of patients with diarrhea or nausea/vomiting. Median survival and response rates were not significantly different after the two treatment schedules.
Similar articles
-
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.Am J Clin Oncol. 1983 Apr;6(2):181-6. doi: 10.1097/00000421-198304000-00007. Am J Clin Oncol. 1983. PMID: 6402917 Clinical Trial.
-
Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum.Oncology. 1986;43(4):212-5. doi: 10.1159/000226367. Oncology. 1986. PMID: 3088506 Clinical Trial.
-
Phase I-II studies of oral tegafur (ftorafur).J Clin Oncol. 1983 Feb;1(2):107-10. doi: 10.1200/JCO.1983.1.2.107. J Clin Oncol. 1983. PMID: 6422005
-
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.Jpn J Clin Oncol. 2002 Sep;32(9):352-7. doi: 10.1093/jjco/hyf072. Jpn J Clin Oncol. 2002. PMID: 12417601
-
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].Gan To Kagaku Ryoho. 2000 Jun;27(6):832-45. Gan To Kagaku Ryoho. 2000. PMID: 10897209 Review. Japanese.
Cited by
-
New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.Pharm World Sci. 1994 Apr 15;16(2):84-103. doi: 10.1007/BF01880660. Pharm World Sci. 1994. PMID: 7518280 Review.
-
Oral versus intravenous fluoropyrimidines for colorectal cancer.Cochrane Database Syst Rev. 2017 Jul 28;7(7):CD008398. doi: 10.1002/14651858.CD008398.pub2. Cochrane Database Syst Rev. 2017. PMID: 28752564 Free PMC article.
-
5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.Med Oncol Tumor Pharmacother. 1991;8(4):271-80. doi: 10.1007/BF02987197. Med Oncol Tumor Pharmacother. 1991. PMID: 1840305
-
Interventions for preventing oral mucositis for patients with cancer receiving treatment.Cochrane Database Syst Rev. 2011 Apr 13;2011(4):CD000978. doi: 10.1002/14651858.CD000978.pub5. Cochrane Database Syst Rev. 2011. PMID: 21491378 Free PMC article.
-
Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation.Clin Transl Oncol. 2006 Jul;8(7):500-7. doi: 10.1007/s12094-006-0050-8. Clin Transl Oncol. 2006. PMID: 16870540
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources